ReviewTrends in pharmacological sciences2016
Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.
Review in Trends in pharmacological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.Human vaccines & immunotherapeutics · 2017Trial
- Antibiotic-resistant infections cured by calcium deposition.Nature biotechnology · 2026Article
- Passive immunization through polyclonal antibodies against IsdE showed protective activity in an experimental S.aureus challenge model.Folia microbiologica · 2026Article
- Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains.Frontiers in immunology · 2026Article
- EPY001, a Novel Monoclonal Antibody AgainstInternational journal of molecular sciences · 2025Article
- Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.AMB Express · 2025Article
- The virulence toolkit of Staphylococcus aureus: a comprehensive review of toxin diversity, molecular mechanisms, and clinical implications.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Antibiotics re-booted-time to kick back against drug resistance.npj antimicrobials and resistance · 2025Review
- Review
- Design of a multi-epitope vaccine against Staphylococcus Aureus lukotoxin ED using in silico approaches.Scientific reports · 2025Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Protective effects of Staphylococcal Enterotoxin B (SEB) toxoid on lung and liver tissue integrity in rats during systemic infection.Iranian journal of microbiology · 2025Article
- Potent human antibodies against SpA5 identified by high-throughput single-cell sequencing of phase I clinical volunteers' B cells.iScience · 2025Article
- Antimicrobial Resistance: A Rising Global Threat to Public Health.Infection and drug resistance · 2025Review
- Methicillin-resistantCurrent pharmaceutical biotechnology · 2025Review
- Single-cell Sequencing of Circulating Human Plasmablasts during Staphylococcus aureus Bacteremia.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Evaluation of human antibodies from vaccinated volunteers for protection againstMicrobiology spectrum · 2024Article
- Surface-Shaving ofMicroorganisms · 2024Article
- Article
- TPST2-mediated receptor tyrosine sulfation enhances leukocidin cytotoxicity andFrontiers in immunology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
The growing incidence of serious infections mediated by methicillin-resistant Staphylococcus aureus (MRSA) strains poses a significant risk to public health. This risk is exacerbated by a prolonged void in the discovery and development of truly novel antibiotics and the absence of a vaccine. These gaps have created renewed interest in the use of biologics in the prevention and treatment of serious staphylococcal infections. In this review, we focus on efforts towards the discovery and development of antibody-based biologic agents and their potential as clinical agents in the management of serious S. aureus infections. Recent promising data for monoclonal antibodies (mAbs) targeting anthrax and Ebola highlight the potential of antibody-based biologics as therapeutic agents for serious infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.